DSG2 and prostate carcinoma: The results presented in this study provide the first molecular characterization of desmoglein expression in normal human prostate, characterization of DSG2 in metastatic prostate cancer cell lines, and the first analysis of DSG2 expression in tissue samples of primary prostatic carcinoma.